Literature DB >> 6110709

Myasthenic syndrome: effect of choline, plasmapheresis and tests for circulating factor.

H Kranz, D J Caddy, A M Williams, W Gay.   

Abstract

In a patient with myasthenic syndrome neuro-muscular transmission was characterised by depression and facilitation. The relative extent of these two processes varied between muscles, and in the one muscle with time. Guanidine HCl treatment corrected the electrophysiological defect. Oral choline increased muscle action potential amplitude in response to single shocks. Intravenous choline produced features indicating cholinergic autonomic stimulation. Pimozide and plasmapheresis had no effect. Animal in-vivo and in-vitro studies performed to detect a circulating factor which interferes with neuro-muscular transmission were negative.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6110709      PMCID: PMC490587          DOI: 10.1136/jnnp.43.6.483

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  20 in total

1.  Myasthenia gravis with features of the myasthenic syndrome. An investigation with electrophysiologic methods including single-fiber electromyography.

Authors:  M S Schwartz; E Stålberg
Journal:  Neurology       Date:  1975-01       Impact factor: 9.910

2.  Distribution and metabolism of intravenously administered choline[methyl- 3-H] and synthesis in vivo of acetylcholine in various tissues of guinea pigs.

Authors:  D R Haubrich; P F Wang; P W Wedeking
Journal:  J Pharmacol Exp Ther       Date:  1975-04       Impact factor: 4.030

3.  Quantal components of end-plate potentials in the myasthenic syndrome.

Authors:  E H Lambert; D Elmqvist
Journal:  Ann N Y Acad Sci       Date:  1971-09-15       Impact factor: 5.691

4.  Temperature and weather correlates of myasthenic fatigue.

Authors:  S Borenstein; J E Desmedt
Journal:  Lancet       Date:  1974-07-13       Impact factor: 79.321

5.  Detailed analysis of neuromuscular transmission in a patient with the myasthenic syndrome sometimes associated with bronchogenic carcinoma.

Authors:  D Elmqvist; E H Lambert
Journal:  Mayo Clin Proc       Date:  1968-10       Impact factor: 7.616

6.  Intermittent defect of acetylcholine release in myasthenia gravis.

Authors:  M Takamori; L Gutmann
Journal:  Neurology       Date:  1971-01       Impact factor: 9.910

7.  Synthesis of acetylcholine in different compartments of brain nerve terminals in vivo as studied by the incorporation of choline from plasma and the effect of pentobarbital on this process.

Authors:  S M Aquilonius; F Flentge; J Schuberth; B Sparf; A Sundwall
Journal:  J Neurochem       Date:  1973-06       Impact factor: 5.372

8.  Choline: selective accumulation by central cholinergic neurons.

Authors:  M J Kuhar; V H Sethy; R H Roth; G K Aghajanian
Journal:  J Neurochem       Date:  1973-02       Impact factor: 5.372

9.  Temperature sensitivity of the time course of facilitation of transmitter release.

Authors:  R J Balnave; P W Gage
Journal:  Brain Res       Date:  1970-07-14       Impact factor: 3.252

10.  Defects of neuromuscular transmission in syndromes other than myasthenia gravis.

Authors:  E H Lambert
Journal:  Ann N Y Acad Sci       Date:  1966-01-26       Impact factor: 5.691

View more
  1 in total

1.  Cancer-associated myasthenic (Eaton-Lambert) syndrome: distribution of abnormality and effect of treatment.

Authors:  D A Ingram; G R Davis; M S Schwartz; M Traub; A C Newland; M Swash
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-08       Impact factor: 10.154

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.